Polyrizon reports successful safety study of a formulation of pl-14 allergy blocker in human nasal tissue model

Raanana, israel, april 25, 2025 (globe newswire) -- polyrizon ltd. (nasdaq: plrz) (the “company” or “polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the successful preliminary safety study for a formulation of its pl-14 allergy blocker, marking a significant advancement in the product's development path.
PLRZ Ratings Summary
PLRZ Quant Ranking